Wall Street analysts expect that BIOLASE Inc (NASDAQ:BIOL) will report ($0.06) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for BIOLASE’s earnings. BIOLASE posted earnings per share of ($0.13) in the same quarter last year, which indicates a positive year over year growth rate of 53.8%. The company is expected to issue its next quarterly earnings results on Tuesday, March 3rd.

On average, analysts expect that BIOLASE will report full-year earnings of ($0.69) per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.36) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover BIOLASE.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of BIOLASE from a “sell” rating to a “hold” rating in a report on Tuesday, January 7th. ValuEngine raised shares of BIOLASE from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. BIOLASE has an average rating of “Buy” and an average target price of $2.17.

NASDAQ:BIOL traded up $0.04 during trading hours on Friday, reaching $0.66. The company’s stock had a trading volume of 105,167 shares, compared to its average volume of 202,135. The firm has a market capitalization of $18.57 million, a price-to-earnings ratio of -0.67 and a beta of 2.19. The firm has a 50-day simple moving average of $0.64 and a 200-day simple moving average of $0.81. BIOLASE has a 1 year low of $0.43 and a 1 year high of $2.87. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.84 and a current ratio of 1.66.

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in BIOLASE by 3.4% in the 2nd quarter. BlackRock Inc. now owns 298,875 shares of the medical technology company’s stock worth $440,000 after acquiring an additional 9,698 shares during the last quarter. Vanguard Group Inc. grew its holdings in BIOLASE by 487.2% in the 2nd quarter. Vanguard Group Inc. now owns 958,247 shares of the medical technology company’s stock worth $1,408,000 after acquiring an additional 795,067 shares during the last quarter. Perkins Capital Management Inc. bought a new stake in BIOLASE in the 4th quarter worth $729,000. Finally, Archon Capital Management LLC grew its holdings in BIOLASE by 61.6% in the 4th quarter. Archon Capital Management LLC now owns 2,675,427 shares of the medical technology company’s stock worth $1,479,000 after acquiring an additional 1,019,835 shares during the last quarter. 26.88% of the stock is currently owned by institutional investors and hedge funds.

BIOLASE Company Profile

BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.

Read More: What are the qualifications of a portfolio manager?

Get a free copy of the Zacks research report on BIOLASE (BIOL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.